O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is Alabama’s only cancer center designated by the National Cancer Institute and is a national leader in driving cancer research, advancing new cancer treatments, engaging communities in cancer prevention and early detection initiatives, and training the next generation of cancer physicians and scientists. Since it was established in 1971, the Cancer Center has been continuously funded for 48 years and has become a world-renowned institution for cancer research, cancer care and the delivery of that care to all people.

Latest from O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham

Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate Cancer

November 12, 2020

Video

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

Dr. Baskin on Treatment Considerations in Prostate Cancer

October 23, 2020

Video

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Triplet Regimens Dominate the Relapsed/Refractory Myeloma Treatment Landscape

September 22, 2020

Article

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

Quadruplets Poised to Become New Standard in Frontline Transplant-Eligible Myeloma

September 17, 2020

Article

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma

September 14, 2020

Video

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma

September 09, 2020

Video

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.